This Week in Dermatology — Jul 10, 2026

Welcome to This Week in Dermatology. This week we are covering ten notable papers spanning advanced management strategies for skin cancer, novel therapeutic insights in atopic dermatitis, and optimizing procedural and wound care outcomes. Let us dive in.

We begin with atopic dermatitis, where new real-world data are helping clinicians optimize long-term maintenance and tailor therapies for specific patient populations. First, a retrospective study published in the Journal of the American Academy of Dermatology evaluated the feasibility of tapering the oral Janus kinase inhibitor abrocitinib over twenty-four weeks in seventy-eight patients with moderate-to-severe disease who had achieved an adequate clinical response [2]. The investigators compared two tapering methods: dose reduction in thirty-six patients and interval extension in forty-two patients. Tapering was remarkably successful, achieved in over ninety-seven percent of patients, with non-relapse rates of over ninety-seven percent at week twelve and ninety-one percent at week twenty-four. This strategy led to a mean cumulative dose reduction of nearly ten thousand milligrams and substantial cost savings. However, clinicians should note that patients who extended their dosing intervals had a significantly higher rate of strategy-switching due to disease fluctuation, at nearly twenty-nine percent compared to just over eight percent in the dose-reduction group, suggesting that lowering the daily dose may offer a more stable tapering course than spacing out doses. Meanwhile, in Clinical and Experimental Dermatology, a multicenter Italian study evaluated the real-world effectiveness and safety of the interleukin-thirteen inhibitor lebrikizumab in ninety elderly patients aged sixty years and older with moderate-to-severe atopic dermatitis [5]. Over fifty-two weeks, the mean Eczema Area and Severity Index decreased dramatically from over twenty-three at baseline to under three. The proportion of patients achieving a seventy-five percent improvement in their severity index rose from fifty-eight percent at week sixteen to eighty-seven percent by week fifty-two, with similar responses across age groups regardless of prior biologic or Janus kinase inhibitor exposure. Adverse events were rare, occurring in fewer than eight percent of patients and remaining mostly mild, confirming that lebrikizumab is both highly effective and safe in older populations.

Next, we turn to basal cell carcinoma management, highlighted by two key publications from Acta Dermato-Venereologica. In a massive nationwide registry study from Denmark analyzing over one hundred and thirty thousand tumors over an eight-year follow-up period, researchers compared recurrence rates across different treatment modalities [3]. For nodular basal cell carcinoma, standard surgical excision demonstrated the lowest rate of recurrence, with an eight-year cumulative recurrence rate of sixteen point five percent and a twenty percent lower hazard of recurrence compared to curettage. For superficial basal cell carcinoma, standard excision and curettage performed equally well, both showing an identical eight-year cumulative recurrence rate of sixteen point three percent. A machine-learning model identified facial location, larger tumor size, a high number of hospital-registered diagnoses, and close proximity to a dermatology clinic as key predictors of recurrence. Addressing the economic and resource implications of surgical selection, another study in the same journal compared healthcare resource utilization and direct costs of Mohs micrographic surgery versus traditional surgical excision for high-risk facial basal cell carcinomas [7]. While Mohs micrographic surgery was associated with higher initial costs, it led to a slower accumulation of healthcare costs over time. Crucially, patients who initially underwent traditional surgery but subsequently failed and required Mohs surgery incurred the highest total costs, often after undergoing multiple prior procedures. This highlights primary Mohs micrographic surgery as a highly cost-efficient strategy for high-risk facial lesions by preventing expensive downstream failures. In a related safety assessment, a study in the Journal of the American Academy of Dermatology explored skin cancer risk specifically in systemic sclerosis patients who have undergone organ transplantation, emphasizing the need for heightened surveillance in this medically complex cohort [9].

Moving to therapeutic safety and wound care, we examine a systematic review in Clinical and Experimental Dermatology that quantified the risk of acneiform eruptions associated with deucravacitinib, a selective tyrosine kinase two inhibitor used for chronic plaque psoriasis [4]. Analyzing fourteen studies representing over five thousand patients, the researchers found that nearly nine percent of patients developed an acneiform eruption, with acne making up over seventy percent of these events, followed by folliculitis at twenty-three percent. Across controlled trials, patients taking deucravacitinib had more than four and a half times the odds of developing these eruptions compared to those on placebo, with higher odds observed at greater daily doses and in patients treated for psoriasis or inflammatory bowel disease. Fortunately, these events rarely led to treatment discontinuation, occurring in only zero point two percent of patients, meaning reassurance and standard acne therapies are generally sufficient. In the realm of wound care, the PLoS Medicine journal published the VENous Ulcer Study 6, a pragmatic randomized controlled trial across thirty-three sites in the United Kingdom comparing compression wraps and two-layer compression bandages against standard evidence-based compression, which includes four-layer bandages or two-layer hosiery, for venous leg ulcers [1]. Among over six hundred participants, two-layer bandages demonstrated non-inferiority to standard evidence-based compression under a treatment policy strategy, with a hazard ratio of one point zero one. However, compression wraps actually resulted in slower healing times compared to standard evidence-based compression, with a hazard ratio of zero point seven eight, and did not show superiority to two-layer bandages. Although the trial was limited by frequent treatment departures and lower-than-expected overall healing rates, the findings suggest that compression wraps are unlikely to accelerate healing compared to traditional bandaging or hosiery.

Finally, we highlight several diagnostic and procedural advancements published in the Journal of the American Academy of Dermatology. To improve the detection of non-bullous pemphigoid, a ten-year large-scale retrospective case-control study established clinical predictors and developed a novel diagnostic nomogram to aid clinicians in early identification [6]. For procedural guidance, another study demonstrated that evaluating the compression response during ultrasound imaging helps clinicians achieve real-time differentiation between pseudocysts and active tunnels in patients with hidradenitis suppurativa, offering a practical bedside tool to guide surgical and medical decisions [8]. Additionally, a new technique utilizing near-infrared vascular mapping was introduced to guide the procedural management of superficial cutaneous vascular lesions, enhancing precision and minimizing complications during targeted interventions [10].

If you only have time for one paper this week, make it the nationwide Danish registry study on basal cell carcinoma recurrence published in Acta Dermato-Venereologica [3]. This landmark study of over one hundred and thirty thousand tumors provides invaluable, long-term real-world data confirming that standard excision remains superior to curettage for nodular basal cell carcinoma, while establishing that curettage is highly comparable to excision for superficial variants.

Here are the key takeaways from this week in Dermatology. First, when tapering abrocitinib in stable atopic dermatitis patients, reducing the daily dose is associated with fewer disease fluctuations and fewer strategy switches than extending the dosing interval. Second, lebrikizumab is highly effective and well-tolerated in elderly patients with moderate-to-severe atopic dermatitis, showing progressive improvement up to one year regardless of previous systemic therapies. Third, while Mohs micrographic surgery carries higher upfront costs for high-risk facial basal cell carcinomas, it is highly cost-effective in the long term by preventing the substantial cumulative costs associated with traditional surgical failures. Fourth, deucravacitinib therapy significantly increases the risk of mild-to-moderate acneiform eruptions, but these events are manageable and rarely require treatment discontinuation. Finally, for venous leg ulcers, compression wraps do not shorten healing times compared to traditional two-layer or four-layer compression systems, which remain the preferred standards of care.

That is your roundup for This Week in Dermatology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.